Decoding
what life wrote
Life has been writing for 3 billion years. 97% has never been read.
Generare generate high-quality molecular data on chemistry that no one, including AI, has ever seen.
Our platform unearth, decodes, and compounds what 3 billion years of evolution wrote into microbial DNA, to spearhead a new paradigm for drug discovery
unearth
We unearth microbial chemistry from the 97% of biodiversity that remains unread. Evolution selected each of these molecules over millions of years for their ability to hit biological targets
decode
Our platform decodes this cryptic chemistry at industrial scale, extracting, purifying, identifying, and annotating molecules in real biological conditions. Each one a new data point that never existed before.
compound
Once discovered, we decode the natural function of these molecules to turn them into first-in-class medicine, from antibiotics to cancer therapies. Each discovery enriches our dataset, improving the next round of predictions.
500
FDA approved drugs
More than 500 FDA-approved drugs originate from microbial chemistry. Penicillin, rapamycin, vancomycin -- all evolution-derived. Then the field moved on. Not because the chemistry ran out, but because the tools to read it didn't exist
Bleomycin
Rapamycin
Daptomycin
Vancomycin
Erythromycin
Penicillin
Cyclosporine
Streptomycin
Bleomycin Rapamycin Daptomycin Vancomycin Erythromycin Penicillin Cyclosporine Streptomycin
97%
Unread
97% of microbial chemistry has never been expressed, observed, or screened. Not because it lacks value -- because the technology to access it didn't exist. Until now
-
We access the 97% of microbial chemistry that has never been screened. Our platform characterizes novel, evolution-derived molecules at a pace no other company matches -- each one a proprietary data point that no AI model has ever been trained on
-
Every molecule enriches the dataset. Richer data sharpens selection. Sharper selection surfaces more novel molecules. Quality feeds novelty, novelty feeds quality. This feedback loop builds an advantage that compounds with every cycle.
-
Our partners access molecules shaped by 3 billion years of evolution, with bioactive properties no synthetic library can replicate. Every structure is a potential drug starting point. None of it exists in any public database. Feed it to an AI model, and the impact multiplies
How it compounds
Join the team
Based in Paris. Computational biologists, chemists, microbiologists, technicians and engineers building the infrastructure to decode what life wrote and turn it into medicine. We are hiring
